Although inhibiting FOSL1/FOSL1 pharmacologically may be challenging due to its oncogenic function, targeting therapy using techniques such as CRISPR/Cas9 or PROTAC that target FOSL1/FOSL1 ectopic expression could be a promising strategy to treat patients with mesenchymal GBM [46]. This evidence concerns the gene FOSL1 and glioblastoma.